Cancer micrometastasis and tumour dormancy
- 1 July 2008
- Vol. 116 (7-8), 754-770
- https://doi.org/10.1111/j.1600-0463.2008.01033.x
Abstract
Many epithelial cancers carry a poor prognosis even after curative resection of early stage tumours. Tumour progression in these cancer patients has been attributed to the existence and persistence of disseminated tumour cells (DTC) in various body compartments as a sign of minimal residual disease. Bone marrow (BM) has been shown to be a common homing organ and reservoir for DTC. A significant correlation between the presence of DTC in BM and metastatic relapse has been reported in various tumour types. However, only a portion of patients with DTC in BM at primary surgery relapse. Thus far, little is known about the conditions required for the persistence of dormancy or the escape from the dormant phase into the active phase of metastasis formation. Thereby, this peculiar stage of conceivably balanced tumour cell division and death may last for decades in cancer patients. Most likely, the ability of a dormant DTC to "be activated" is a complex process involving (i) somatic aberrations in the tumour cells, (ii) the interaction of the DTC with the new microenvironment at the secondary site, and (iii) hereditary components of the host (i.e., cancer patient). In this review, we will summarize the key findings of research on micrometastatic cancer cells and discuss these findings in the context of the concept of tumour dormancy.Keywords
This publication has 102 references indexed in Scilit:
- Metastasis: recent discoveries and novel treatment strategiesThe Lancet, 2007
- Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancerMolecular Oncology, 2007
- A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementationCancer, 2006
- Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patientsBreast Cancer Research and Treatment, 2006
- Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancerCancer Cell, 2005
- The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrenceCancer, 2005
- MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancerNature, 2004
- Metastasis genes: A progression puzzleNature, 2002
- Genetic heterogeneity of single disseminated tumour cells in minimal residual cancerThe Lancet, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002